316 related articles for article (PubMed ID: 30098419)
1. Prostate cancer sheds the αvβ3 integrin in vivo through exosomes.
Krishn SR; Singh A; Bowler N; Duffy AN; Friedman A; Fedele C; Kurtoglu S; Tripathi SK; Wang K; Hawkins A; Sayeed A; Goswami CP; Thakur ML; Iozzo RV; Peiper SC; Kelly WK; Languino LR
Matrix Biol; 2019 Apr; 77():41-57. PubMed ID: 30098419
[TBL] [Abstract][Full Text] [Related]
2. Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.
Lu H; Bowler N; Harshyne LA; Craig Hooper D; Krishn SR; Kurtoglu S; Fedele C; Liu Q; Tang HY; Kossenkov AV; Kelly WK; Wang K; Kean RB; Weinreb PH; Yu L; Dutta A; Fortina P; Ertel A; Stanczak M; Forsberg F; Gabrilovich DI; Speicher DW; Altieri DC; Languino LR
Matrix Biol; 2018 Sep; 70():20-35. PubMed ID: 29530483
[TBL] [Abstract][Full Text] [Related]
3. Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype.
Singh A; Fedele C; Lu H; Nevalainen MT; Keen JH; Languino LR
Mol Cancer Res; 2016 Nov; 14(11):1136-1146. PubMed ID: 27439335
[TBL] [Abstract][Full Text] [Related]
4. Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
Padda RS; Deng FK; Brett SI; Biggs CN; Durfee PN; Brinker CJ; Williams KC; Leong HS
Prostate; 2019 May; 79(6):592-603. PubMed ID: 30680751
[TBL] [Abstract][Full Text] [Related]
5. Prostate field cancerization and exosomes: Association between CD9, early growth response 1 and fatty acid synthase.
Amirrad F; Pytak PA; Sadeghiani-Pelar N; Nguyen JPT; Cauble EL; Jones AC; Bisoffi M
Int J Oncol; 2020 Apr; 56(4):957-968. PubMed ID: 32319557
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression.
Quaglia F; Krishn SR; Wang Y; Goodrich DW; McCue P; Kossenkov AV; Mandigo AC; Knudsen KE; Weinreb PH; Corey E; Kelly WK; Languino LR
PLoS One; 2021; 16(1):e0244985. PubMed ID: 33481853
[TBL] [Abstract][Full Text] [Related]
7. Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer.
Kawakami K; Fujita Y; Matsuda Y; Arai T; Horie K; Kameyama K; Kato T; Masunaga K; Kasuya Y; Tanaka M; Mizutani K; Deguchi T; Ito M
BMC Cancer; 2017 May; 17(1):316. PubMed ID: 28476099
[TBL] [Abstract][Full Text] [Related]
8. Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells.
Liu T; Mendes DE; Berkman CE
Int J Oncol; 2014 Mar; 44(3):918-22. PubMed ID: 24424840
[TBL] [Abstract][Full Text] [Related]
9. Targeting the αVβ3/NgR2 pathway in neuroendocrine prostate cancer.
Testa A; Quaglia F; Naranjo NM; Verrillo CE; Shields CD; Lin S; Pickles MW; Hamza DF; Von Schalscha T; Cheresh DA; Leiby B; Liu Q; Ding J; Kelly WK; Hooper DC; Corey E; Plow EF; Altieri DC; Languino LR
Matrix Biol; 2023 Dec; 124():49-62. PubMed ID: 37956856
[TBL] [Abstract][Full Text] [Related]
10. Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer.
Martens-Uzunova ES; Kusuma GD; Crucitta S; Lim HK; Cooper C; Riches JE; Azad A; Ochiya T; Boyle GM; Southey MC; Del Re M; Lim R; Ramm GA; Jenster GW; Soekmadji C
J Extracell Vesicles; 2021 Aug; 10(10):e12136. PubMed ID: 34434533
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling.
McCabe NP; De S; Vasanji A; Brainard J; Byzova TV
Oncogene; 2007 Sep; 26(42):6238-43. PubMed ID: 17369840
[TBL] [Abstract][Full Text] [Related]
12. Biomolecular characterization of exosomes released from cancer stem cells: Possible implications for biomarker and treatment of cancer.
Kumar D; Gupta D; Shankar S; Srivastava RK
Oncotarget; 2015 Feb; 6(5):3280-91. PubMed ID: 25682864
[TBL] [Abstract][Full Text] [Related]
13. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.
Khan S; Jutzy JM; Valenzuela MM; Turay D; Aspe JR; Ashok A; Mirshahidi S; Mercola D; Lilly MB; Wall NR
PLoS One; 2012; 7(10):e46737. PubMed ID: 23091600
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
Wang YH; Ji J; Wang BC; Chen H; Yang ZH; Wang K; Luo CL; Zhang WW; Wang FB; Zhang XL
Cell Physiol Biochem; 2018; 46(2):532-545. PubMed ID: 29614511
[TBL] [Abstract][Full Text] [Related]
15. The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3.
Yu J; Lee CY; Changou CA; Cedano-Prieto DM; Takada YK; Takada Y
Biochem J; 2017 Feb; 474(4):589-596. PubMed ID: 27993971
[TBL] [Abstract][Full Text] [Related]
16. The αvβ6 integrin is transferred intercellularly via exosomes.
Fedele C; Singh A; Zerlanko BJ; Iozzo RV; Languino LR
J Biol Chem; 2015 Feb; 290(8):4545-4551. PubMed ID: 25568317
[TBL] [Abstract][Full Text] [Related]
17. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
18. α
Wang T; Huang J; Vue M; Alavian MR; Goel HL; Altieri DC; Languino LR; FitzGerald TJ
Mol Cancer Res; 2019 Feb; 17(2):398-408. PubMed ID: 30266752
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer.
Gabriel K; Ingram A; Austin R; Kapoor A; Tang D; Majeed F; Qureshi T; Al-Nedawi K
PLoS One; 2013; 8(7):e70047. PubMed ID: 23936141
[TBL] [Abstract][Full Text] [Related]
20. Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer.
Duijvesz D; Versluis CY; van der Fels CA; Vredenbregt-van den Berg MS; Leivo J; Peltola MT; Bangma CH; Pettersson KS; Jenster G
Int J Cancer; 2015 Dec; 137(12):2869-78. PubMed ID: 26139298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
